Pipeline

Overview

Mission Therapeutics is developing a rich pipeline of first-in-class small molecule DUB inhibitors for a number of significant clinical indications.

We are currently prioritizing several DUB target programs that are based on extensive research around the ~100 human DUBs and their market opportunities.

Our world-leading drug discovery and development platform gives us the opportunity to explore multiple additional DUB targets of relevance to other disease indications, both in-house and through partnerships with other pharmaceutical companies.

Several of our USP30 inhibitor programs are either in the clinic or approaching clinical development.

Placeholder bar. Do NOT delete!

Programs

Compound
Target		Key Clinical Indication(s)DiscoveryPreclinicalPhase IPhase IICommercial Rights
MTX652
USP30		Heart Failure/HFpEF*10010010010
MTX325
USP30		Parkinson’s Disease**10010025
Two DUB targetsAlzheimer’s Diseases0000

Scroll pipeline to left or right

* potential for expansion into Duchenne’s with key benefit on cardiomyopathy

** potential for expansion into other neurodegenerative disorders (e.g., ALS)

Mission Therapeutics © website by Instinctif Partners